Search Result

Results for "

CDV

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CMV (4) DNA/RNA Synthesis (5) Drug Metabolite (1) HSV (4) Isotope-Labeled Compounds (2) Orthopoxvirus (2) RSV (1) Small Interfering RNA (siRNA) (1)
By Research Areas:	Infection (7)
Oligonucleotides:	Phospholipids (1) Human Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14532

Brincidofovir 5 Publications Verification CMX001; HDP-CDV	CMV HSV Orthopoxvirus	Infection
Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo .

HY-131606B

Cidofovir diphosphate tritriethylamine	Drug Metabolite DNA/RNA Synthesis	Infection
Cidofovir diphosphate tri triethylamine is an active intracellular metabolite of Cidofovir. Cidofovir diphosphate tri triethylamine is a selective inhibitor of viral DNA polymerases with K_i values of 6.6, 0.86 and 1.4 μM for HCMV, HSV-1 and HSV-2 DNA polymerase, respectively .

HY-131606

Cidofovir diphosphate	HSV CMV DNA/RNA Synthesis	Infection
Cidofovir diphosphate is an active intracellular metabolite of Cidofovir. Cidofovir diphosphate is a selective inhibitor of viral DNA polymerases with K_i values of 6.6, 0.86 and 1.4 μM for HCMV, HSV-1 and HSV-2 DNA polymerase, respectively .

HY-14532S

Brincidofovir-d6 CMX001-d₆; HDP-CDV-d₆	Isotope-Labeled Compounds HSV CMV Orthopoxvirus	Infection
Brincidofovir-d₆ (CMX001-d₆) is the deuterium labeled Brincidofovir (HY-14532). Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo. .

HY-170395

GHP-88309	RSV DNA/RNA Synthesis	Infection
GHP-88309 is a broad-spectrum, orally active antiviral agent targeting paramyxoviruses, that targets the viral polymerase, interupts the viral RNA synthesis, and inhibits respiratory syncytial virus (RSV), measles virus (MeV), and canine distemper virus (CDV) with EC₅₀ of 0.06-1.2 μM. GHP-88309 exhibits anti-infectious efficacy in mouse models .

HY-RS02428

CDV3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDV3 Human Pre-designed siRNA Set A contains three designed siRNAs for CDV3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDV3 Human Pre-designed siRNA Set A CDV3 Human Pre-designed siRNA Set A

HY-131606S

Cidofovir diphosphate-13C3	Isotope-Labeled Compounds HSV CMV DNA/RNA Synthesis	Infection
Cidofovir diphosphate- ¹³C₃ is the ¹³C-labeled Cidofovir diphosphate (HY-131606). Cidofovir diphosphate is an active intracellular metabolite of Cidofovir. Cidofovir diphosphate is a selective inhibitor of viral DNA polymerases with K_i values of 6.6, 0.86 and 1.4 μM for HCMV, HSV-1 and HSV-2 DNA polymerase, respectively .

HY-180882

GHP-88310 EIDD-3608	DNA/RNA Synthesis	Infection
GHP-88310 (EIDD-3608) is a potent, orally active orthoparamyxovirus polymerases inhibitor. GHP-88310 exhibits potent activity against HPIV3 and related respiroviruses, measles virus (MeV) and related morbilliviruses. GHP-88310 exhibits efficacy in both canine distemper virus (CDV) ferret models and HPIV3 cotton rat models. GHP-88310 can be used for orthoparamyxovirus disease research .

Cat. No.	Product Name	Chemical Structure

HY-14532S

Brincidofovir-d6
Brincidofovir-d₆ (CMX001-d₆) is the deuterium labeled Brincidofovir (HY-14532). Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo. .

Brincidofovir-d6

Brincidofovir-d₆ (CMX001-d₆) is the deuterium labeled Brincidofovir (HY-14532). Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo. .

HY-131606S

Cidofovir diphosphate-13C3
Cidofovir diphosphate- ¹³C₃ is the ¹³C-labeled Cidofovir diphosphate (HY-131606). Cidofovir diphosphate is an active intracellular metabolite of Cidofovir. Cidofovir diphosphate is a selective inhibitor of viral DNA polymerases with K_i values of 6.6, 0.86 and 1.4 μM for HCMV, HSV-1 and HSV-2 DNA polymerase, respectively .

Cat. No.	Product Name		Classification

HY-14532

Brincidofovir 5 Publications Verification CMX001; HDP-CDV		Phospholipids
Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo .

HY-RS02428

CDV3 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CDV3 Human Pre-designed siRNA Set A contains three designed siRNAs for CDV3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.